Table 1. Concentration of B cells in blood of TRAF2DN/Bcl2 mice treated with empty liposomes or with triterpenoids.

mouse ID	Drug	B cells (millions)
	dosage	pre-treatment	1st dosage	2nd dosage	3th dosage	6th dosage	post-treatment
	Liposomes	Day -1	Day 1	Day 2-3	Day 4-6	Day 11-14	Day 24 to 28
310	–	7	8	9	9	6	7
327	–	12	nd	10	8.4	8	12
325	–	13	10	15	13	14	58
420	–	6	7	8	nd	7	13
414	–	5	5	5	5	7	27
413	–	6	8	10	6	23	34
	CDDO
209	20 mg/Kg	26	10	22	21	18	11
332	″	14	8	11	11	14	5
190	″	10	12	6	7	4.5	2.4
300	″	41	26	34	45	48	19.6
	CDDO-Im
614	5 mg/Kg	32	70	77	35	35	12
615	″	5	9	6.4	9	3.2	1.5
655	″	6.6	9.5	10.6	5.3	7.8	2.3
691	″	48	46	64	73	77	21.6
694	″	9.5	19	17	17	7.5	3.1
711	″	134.7	123	119	140	126	58.5
203	10 mg/Kg	14	63	60	71	dead	–
224	″	23	32	24	31	12	2
227	″	13	53	nd	69	dead	–
389	″	9	39	42	50	10	3.3
314	″	4	24	32	15	20	0.6
317	″	7	38	32	20	14	dead
349	″	30	50	47	37	27	0.8
365	″	4.3	21	25	12	5	0.5
382	″	7	14	29	20	dead	–
302	20 mg/Kg	26	240	dead	–	–	–
343	″	16	28	72	21	7	1.5
344	″	15	nd	41	15	2	0.6
369	″	23	140	173	118	dead	–
388	″	49	105	163	130	dead	–

TRAF2DN/Bcl-2 mice were injected i.v. with empty liposomes or with liposomes containing either CDDO or CDDO-Im at doses of 5, 10 or 20 mg/kg/day (corresponding to 17.3, 34.5 and 69 mg/m²/day, respectively). Each mouse received a total of nine injections administered over a period of 21–25 days. The concentration of B cells (×10⁶/ml) in blood was monitored one day before the inoculation with drug (pre-treatment), after the inoculation of the 1^st, 2^nd, 3^rd and 6^th drug dosages, and 3 to 10 days after the final inoculation(post-treatment). (nd: not determined).